ERBB2 and breast carcinoma: Modern clinical studies have shown that 45% of breast cancer patients undergoing blood metastasis after TCM syndrome differentiation, blood stasis, toxin internal resistance, and blood stasis are common in most breast cancer patients, especially in patients with HER-2 breast cancer.